Alphamab and 3D Medicines File China NDA for PD-L1 Therapy

Alphamab Oncology and 3D Medicines filed a China NDA for their partnered anti-PD-L1 therapy as a treatment for MSI-H/dMMR cancer. In a Phase II registration trial, patients with MSI-H/dMMR colorectal cancer experienced an objective response rate of 32%. The patients had previously failed a fluoropyrimidine, oxaliplatin and irinotecan regimen. The results were roughly equivalent to those produced by BMS's Opdivo and Merck's Keytruda. In the US , Tracon Pharma partners the candidate with the two China pharmas. More details.... Stock Symbols: (HK: 9966) (NSDQ: TCON) Share this with colleagues: // //